Specifications
Description | THJ29T Cells are derived from anaplastic thyroid stage IV patient. The cells express p53 Q104X, and ALK S426T oncogenes; and is tumorigenic in athymide nude mice. |
---|---|
SKU | T8254 |
Species | Human (H. sapiens) |
Tissue/Organ/Organ System | Thyroid |
Donor Gender | Female |
Donor Disease | Thyroid gland undifferentiated (anaplastic) carcinoma |
Growth Properties | Adherent |
Cell Morphology | Epithelial-like |
Population Doubling Time | 35 hours |
Applications | For Research Use Only |
Unit quantity | 1×106 cells / 1.0 ml |
Cell Type | Tumor Cells |
Expression Profile | p53 Q104X, ALK S426T |
Propagation Requirements |
Use of PriCoatTM T25 Flasks (G299) or Applied Cell Extracellular Matrix (G422) is required for cell adhesion to the culture vessels. Grow cells in ECM-coated culture vessels unless otherwise specified in the Propagation Requirements below. The base medium for this cell line is Prigrow III medium available at abm, Cat. No. TM003. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (TM999) to a final concentration of 5%, Penicillin/Streptomycin Solution (G255) to a final concentration of 1%, and HEPES to a final concentration of 10 mM. |
Preservation Protocol | 1. Freeze Medium: Complete growth medium with 20% FBS and 10% DMSO. 2. Storage Temperature: Liquid nitrogen vapour phase. |
QC | 1) STR profiling |
Disclaimer |
|
Depositor | Mayo |
There are no FAQs for this product yet!
4
Hitora, T., Yamamoto, T., Akisue, T., Marui, T., Nakatani, T., Kawamoto, T., … & Kurosaka, M. (2005). Establishment and characterization of a KIT‐positive and stem cell factor‐producing cell line, KTHOS, derived from human osteosarcoma. Pathology international, 55(2), 41-47.
Marlow LA, D’Innocenzi J, Zhang Y, Rohl SD, Cooper SJ, Sebo T, Grant C, McIver B, Kasperbauer JL, Wadsworth JT, Casler JD, Kennedy PW, Highsmith WE, Clark O, Milosevic D, Netzel B, Cradic K, Arora S, Beaudry C, Grebe SK, Silverberg ML, Azorsa DO, Smallridge RC, Copland JA. Detailed molecular fingerprinting of four new anaplastic thyroid carcinoma cell lines and their use for verification of RhoB as a molecular therapeutic target. J Clin Endocrinol Metab. 2010 Dec;95(12):5338-47. doi: 10.1210/jc.2010-1421. Epub 2010 Sep 1. Erratum in: J Clin Endocrinol Metab. 2013 Nov;98(11):4546. Erratum in: J Clin Endocrinol Metab. 2013 Oct;98(10):4213. PMID: 20810568; PMCID: PMC2999968.
Li W, Reeb AN, Sewell WA, Elhomsy G, Lin RY. Phenotypic characterization of metastatic anaplastic thyroid cancer stem cells. PLoS One. 2013 May 28;8(5):e65095. doi: 10.1371/journal.pone.0065095. PMID: 23724124; PMCID: PMC3665717.Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimpasic T, Ghossein RA, Fagin JA. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab. 2013 Sep;98(9):E1562-6. doi: 10.1210/jc.2013-2383. Epub 2013 Jul 5. PMID: 23833040; PMCID: PMC3763971.